ISSN (print) 1997-6933     ISSN (online) 2500-2139
Vol. 17 No. 2 (2024), MYELOID TUMORS
Vol. 17 No. 2 (2024)
MYELOID TUMORS

Treatment of Aggressive Systemic Mastocytosis and Mast Cell Leukemia. Literature Review and Case Reports

Published 01.04.2024
Vsevolod Gennadevich Potapenko
City Clinical Hospital No. 31, 3 Dinamo pr-t, Saint Petersburg, Russian Federation, 197110
E.V. Morozova
RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022 3 National Center for Clinical Morphological Diagnosis, 32 Slavy pr-t, Saint Petersburg, Russian Federation, 192071
PDF_2024-17-2_180-194 (Russian)

Keywords

mastocytoses
tryptase
mast cells
mast cell leukemia
KIT gene
cladribine
imatinib

How to Cite

Potapenko V.G., Morozova E.V. Treatment of Aggressive Systemic Mastocytosis and Mast Cell Leukemia. Literature Review and Case Reports. Clinical Oncohematology. 2024;(2):180–194. doi:10.21320/2500-2139-2024-17-2-180-194.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Keywords

Abstract

Aim. To provide case reports on the course and treatment of aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL).

Materials & Methods. This paper reports the histories of adult patients with ASM (n = 4) and MCL (n = 2) treated with cytoreduction predominantly at the City Clinical Hospital No. 31 (Saint Petersburg). The patients were 36–61 years of age (median 50 years); there were 4 women and 2 men.

Results. All patients showed stable response to cladribine (n = 3), imatinib (n = 2), and combined lenalidomide, elotuzumab, and dexamethasone treatment with subsequent allogeneic hematopoietic stem cell transplantation (n = 1). With a median follow-up of 124 months (range 55–186 months), 1 out of 2 MCL patients died due to the concomitant hypereosinophilic syndrome progression and secondary infectious complication.

Conclusion. Cladribine therapy in 2 ASM patients and imatinib therapy in 2 MCL patients yielded stable long-term response with good quality of life being maintained. More comparative studies are required for efficacy assessment and optimum sequencing of chemotherapeutic drugs.

PDF_2024-17-2_180-194 (Russian)

References

  1. Branford WA. Edward Nettleship (1845–1913) and the description of urticaria pigmentosa. Int J Dermatol. 1994;33(3):214–6. doi: 10.1111/j.1365-4362.1994.tb04957.x.
  2. Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am. 2014;34(2):283–95. doi: 10.1016/j.iac.2014.01.003.
  3. Lawrence JB, Friedman BS, Travis WD, et al. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med. 1991;91(6):612–24. doi: 10.1016/0002-9343(91)90214-i.
  4. Valent P, Sperr WR, Schwartz LB, et al. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol. 2004;114(1):3–11. doi: 10.1016/j.jaci.2004.02.045.
  5. Kristensen T, Vestergaard H, Bindslev-Jensen C, et al. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol. 2014;89(5):493–8. doi: 10.1002/ajh.23672.
  6. Valent P, Akin C, Nedoszytko B, et al. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. Int J Mol Sci. 2020;21(23):9030. doi: 10.3390/ijms21239030.
  7. Sperr WR, Jordan JH, Fiegl M, et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol. 2002;128(2):136–41. doi: 10.1159/000059404.
  8. Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123(3):680–6. doi: 10.1016/j.jaci.2008.11.018.
  9. Zanotti R, Lombardo C, Passalacqua G, et al. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol. 2015;136(1):135–9. doi: 10.1016/j.jaci.2014.11.035.
  10. Metcalfe DD, Schwartz LB. Assessing anaphylactic risk? Consider mast cell clonality. J Allergy Clin Immunol. 2009;123(3):687–8. doi: 10.1016/j.jaci.2009.02.003.
  11. Khoury JD, Solary E, Abla O, et al. The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19. doi: 10.1038/s41375-022-01613-1.
  12. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25(7):603–25. doi: 10.1016/s0145-2126(01)00038-8.
  13. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727–36. doi: 10.1182/blood-2009-02-205237.
  14. Потапенко В.Г., Байков В.В., Белоусова И.Э. и др. Мастоцитоз у взрослых: ретроспективный анализ клинического течения и терапии у 58 пациентов. Клиническая онкогематология. 2021;14(2):158–66. doi: 10.21320/2500-2139-2021-14-2-158-166. [Potapenko VG, Baikov VV, Belousova IE, et al. Mastocytosis in Adults: A Retrospective Analysis of the Clinical Course and Treatment of 58 Patients. Clinical oncohematology. 2021;14(2):158–66. doi: 10.21320/2500-2139-2021-14-2-158-166. (In Russ)]
  15. Valent P, Oude Elberink JNG, Gorska A, et al. The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. J Allergy Clin Immunol Pract. 2019;7(1):81–7. doi: 10.1016/j.jaip.2018.09.024.
  16. Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009;33(11):1481–4. doi: 10.1016/j.leukres.2008.12.020.
  17. Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA. 1999;96(4):1609–14. doi: 10.1073/pnas.96.4.1609.
  18. Barete S, Lortholary O, Damaj G, et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015;126(8):1009–16. doi: 10.1182/blood-2014-12-614743.
  19. Elmaagacli AH, Jehn C, Shikova Y, et al. Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide. Leuk Lymphoma. 2020;61(2):485–7. doi: 10.1080/10428194.2019.1668939.
  20. Purtill D, Cooney J, Sinniah R, et al. Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol. 2008;80(5):456–8. doi: 10.1111/j.1600-0609.2008.01048.x.
  21. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016;374(26):2530–41. doi: 10.1056/NEJMoa1513098.
  22. DeAngelo DJ, Quiery AT, Radia D, et al. Clinical activity in a phase 1 study of Blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (AdvSM). Blood. 2017;130(Suppl 1):2. doi: 10.1182/blood.V130.Suppl_1.2.2.
  23. Kasamon YL, Ko CW, Subramaniam S, et al. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis. Oncologist. 2018;23(12):1511–9. doi: 10.1634/theoncologist.2018-0222.
  24. Reiter A, Schwaab J, DeAngelo DJ, et al. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Adv. 2022;6(21):5750–62. doi: 10.1182/bloodadvances.2022007539.
  25. Pilkington H, Smith S, Roskell N, et al. Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis. Future Oncol. 2022;18(13):1583–94. doi: 10.2217/fon-2021-1509.
  26. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Available from: https://bloodjournal.ru/dlya-avtorov-2/#av5 (accessed 14.05.2023).
  27. Потапенко В.Г., Скорюкова К.А., Лисукова Е.В. и др. Мастоцитоз у детей. Клиническая и лабораторная характеристика группы 111 пациентов. Педиатрия. 2018;97(4):135–40. doi: 10.24110/0031-403X-2018-97-4-135-140. [Potapenko VG, Skoryukova KA, Lisukova YV, et al. Mastocytosis in children. Characteristic of a group of 111 patients. Pediatria. 2018;97(4):135–40. doi: 10.24110/0031-403X-2018-97-4-135-140. (In Russ)]
  28. Potapenko VG, Talypov SR. Severe course of cutaneous mastocytosis in a child. Case report. Cell Ther Transplant 2022;11(2):58–62. doi: 10.18620/ctt-1866-8836-2022-11-2-58-62.
  29. Потапенко В.Г., Байков В.В., Бойченко Э.Г. и др. Проспективное исследование 163 пациентов с помощью дистанционного анкетирования родителей. Российский журнал детской гематологии и онкологии. 2021;8(2):13–25. doi: 10.21682/2311-1267-2021-8-2-13-25. [Potapenko VG, Baykov VV, Boychenko EG, et al. The clinical course of cutaneous mastocytosis in a prospective group of 163 children according to electronic parent survey. Russian Journal of Pediatric Hematology and Oncology. 2021;8(2):13–25. doi: 10.21682/2311-1267-2021-8-2-13-25. (In Russ)]
  30. Мастоцитоз у детей и взрослых. Рекомендации для пациентов и их близких (электронный документ). Доступно по: https://spbsverdlovka.ru/patsientam/biblioteka-patsienta/mastotsitoz-u-detej-i-vzroslykh-rekomendatsii-dlya-patsientov-i-ikh-blizkikh.html. Ссылка активна на 23.06.2023. [Mastocytosis in children and adults. Recommendations for patients and their families (Internet). Available from: https://spbsverdlovka.ru/patsientam/biblioteka-patsienta/mastotsitoz-u-detej-i-vzroslykh-rekomendatsii-dlya-patsientov-i-ikh-blizkikh.html. Accessed 23.06.2023. (In Russ)]
  31. О мастоцитозе из первых рук. Видеотрансляция (электронный документ). Доступно по: https://spbsverdlovka.ru/patsientam/biblioteka-patsienta/o-mastotsitoze-iz-pervykh-ruk-videotranslyatsiya.html. Ссылка активна на 23.06.2023. [On mastocytosis: first-hand evidence. A video broadcast (Internet). Available from: https://spbsverdlovka.ru/patsientam/biblioteka-patsienta/o-mastotsitoze-iz-pervykh-ruk-videotranslyatsiya.html. Accessed 23.06.2023. (In Russ)]
  32. Цветовая дуплексная сонография. Практическое руководство. Под ред. М. Хофера. М.: Медицинская литература, 2007. 108 с. [Hofer M, ed. Tsvetovaya dupleksnaya sonografiya. Prakticheskoe rukovodstvo. (Color duplex sonography. Practice guide.) Moscow: Meditsinskaya literatura Publ.; 2007. 108 p. (In Russ)]
  33. Zhang R, Jin G, Zhan Y, et al. Allergic Bronchopulmonary Mycosis Caused by Mucor Overlapping with Invasive Pulmonary Mucormycosis: A Case Report. Front Med (Lausanne). 2022;9:831213. doi: 10.3389/fmed.2022.831213.
  34. Hirano T, Yamada M, Sato K, et al. Invasive pulmonary mucormycosis: rare presentation with pulmonary eosinophilia. BMC Pulm Med. 2017;17(1):76. doi: 10.1186/s12890-017-0419-1.
  35. Tang X, Guo P, Wong H, et al. Vacuum-Assisted Closure and Skin Grafting Combined with Amphotericin B for Successful Treatment of an Immunocompromised Patient with Cutaneous Mucormycosis Caused by Mucor irregularis: A Case Report and Literature Review. Mycopathologia. 2021;186(3):449–59. doi: 10.1007/s11046-021-00551-3.
  36. Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy. 2004;59(7):673–89. doi: 10.1111/j.1398-9995.2004.00465.x.
  37. Sperr WR, Kundi M, Alvarez-Twose I, et al. international prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019;6(12):e638–е649. doi: 10.1016/S2352-3026(19)30166-8.
  38. De Schryver S, Halbrich M, Clarke A, et al. Tryptase levels in children presenting with anaphylaxis: Temporal trends and associated factors. J Allergy Clin Immunol. 2016;137(4):1138–42. doi: 10.1016/j.jaci.2015.09.001.
  39. Van Der Veer E, Van Der Goot W, De Monchy JGR, et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy Eur J Allergy Clin Immunol. 2012;67(3):431–8. doi: 10.1111/j.1398-9995.2011.02780.x.
  40. Riffel P, Schwaab J, Lutz C, et al. An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis. J Cancer Res Clin Oncol. 2020;146(4):945–51. doi: 10.1007/s00432-019-03119-3.
  41. Rossini M, Zanotti R, Viapiana O, et al. Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med. 2014;127(11):1127.e1–1127.e4. doi: 10.1016/j.amjmed.2014.06.015.
  42. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102(13):4270–6. doi: 10.1182/blood-2003-05-1699.
  43. Tefferi A, Kittur J, Farrukh F, et al. Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. Br J Haematol. 2022;196(4):975–83. doi: 10.1111/bjh.17932.
  44. Helbig G, Koclęga A, Gaweł WB, et al. The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis. Indian J Hematol Blood Transfus. 2020;36(4):661–6. doi: 10.1007/s12288-020-01279-8.
  45. Singh A, Al-Kali A, Begna KH, et al. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. Am J Hematol. 2022;97(5):630–7. doi: 10.1002/ajh.26498.
  46. DeAngelo DJ, George TI, Linder A, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32(2):470–8. doi: 10.1038/leu.2017.234.
  47. Szudy-Szczyrek A, Bachanek-Mitura O, Gromek T, et al. Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis. J Clin Med. 2021;10(5):1109. doi: 10.3390/jcm10051109.
  48. RYDAPT® (midostaurin) capsules, for oral use. Initial U.S. Approval: 2017. Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf (accessed 14.06.2023).
  49. Reiter A, Gotlib J, Alvarez-Twose I, et al. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia. 2022;36(8):2108–20. doi: 10.1038/s41375-022-01615-z.
  50. Lubke J, Schwaab J, Naumann N, et al. Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis. J Clin Oncol. 2022;40(16):1783–94. doi: 10.1200/JCO.21.01849.
  51. Chandesris MO, Damaj G, Canioni D, et al. Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016;374(26):2605–7. doi: 10.1056/NEJMc1515403.
  52. Gotlib J, Reiter A, Radia DH, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021;27(12):2192–9. doi: 10.1038/s41591-021-01539-8.
  53. Sperr WR, Drach J, Hauswirth AW, et al. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res. 2005;11(19 Pt 1):6787–92. doi: 10.1158/1078-0432.CCR-05-1064.
  54. Ustun C, Gotlib J, Popat U, et al. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant. 2016;22(8):1348–56. doi: 10.1016/j.bbmt.2016.04.018.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2024 Clinical Oncohematology